Sleepiness in Parkinson's Patients With Continuous Dopaminergic Delivery Device or Deep Brain Stimulation

NCT ID: NCT04441697

Last Updated: 2021-08-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-01

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sleepiness is frequent in parkinsonian patients, increasing with the duration of disease. By patients with motor fluctuations, continuous dopaminergic delivery devices or deep brain stimulation are justified to improve the motor prognosis. Antiparkinsonian treatments, especially dopaminergic agonists, may worsen the sleepiness and thus affect the quality of life. The investigators aimed to monitor sleepiness in parkinsonian patients before and during treatment with continous dopaminergic delivery device or deep brain stimulation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

continuous apomorphine delivery

apomorphine, subcutaneous administration, continuous delivery during 8 to 24 hours/day

Multiple sleep latency tests

Intervention Type DIAGNOSTIC_TEST

The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.

continous levodopa/carbidopa delivery

levodopa/carbidopa monohydrate, jejunal administration, continuous delivery during 8 to 24 hours/day

Multiple sleep latency tests

Intervention Type DIAGNOSTIC_TEST

The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.

deep brain stimulation

bilateral subthalamic electrical stimulation, intracranial neurosurgical electrodes, individual electrical parameters settings

Multiple sleep latency tests

Intervention Type DIAGNOSTIC_TEST

The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multiple sleep latency tests

The investigators measure the objective sleepiness by recording the electro-encephalogramm during four experimental diurnal naps. They also perform a nocturnal polysomnography prior to the tests for a better interpretation.

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Polysomnography

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient with Parkinson's disease and motor fluctuations
* and indicated for a continuous dopaminergic delivery device or deep brain stimulation

Exclusion Criteria

* age \< 18 years
* refusal for the continuous dopaminergic delivery device or deep brain stimulation
* wake-promoting drugs intake
* refusal to participate
* legal protection
* uncontrolled sleep apnea
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Central Hospital, Nancy, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

El Mehdi Siaghy

Role: STUDY_CHAIR

Research and Innovation Department

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nancy University Hospital

Nancy, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nicolas Carpentier

Role: CONTACT

0033383858585

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nicolas Carpentier

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020PI085

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Deep Brain Stimulation and Parkinson's Disease
NCT02795663 COMPLETED EARLY_PHASE1
Connectomic Guided DBS for Parkinson's Disease
NCT06618157 ENROLLING_BY_INVITATION NA
Psychiatry Study: Parkinson Disease
NCT02893449 COMPLETED NA